Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: GlobeNewswire
Dr. Schottelius, former executive at Kymab, MorphoSys and Genentech, brings extensive innate immunity expertise and successful record of advancing discovery research into preclinical and clinical development Heidelberg, Germany, March 17, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020. Dr. Schottelius will lead Affimed’s discovery, translational innovation and platform engineering teams. In addition, Dr. Schottelius will lead the company’s preclinical development activities, initiatives to generate additional innate cell engagers based on its proprietary fit-for-purpose ROCK® (Redirected Optimized Cell Killing) platform and efforts to strengthen Affimed’s intellectual property. Dr. Schottelius will also take a lead role in furthering Affimed’s ongoing Genentech partnership and o
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "hold" rating on the stock.MarketBeat
- Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Affimed Reports Third Quarter 2024 Financial Results & Business UpdateGlobeNewswire
- Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024GlobeNewswire
AFMD
Earnings
- 11/14/24 - Beat
AFMD
Sec Filings
- 11/14/24 - Form 6-K
- 11/12/24 - Form EFFECT
- 11/8/24 - Form 424B5
- AFMD's page on the SEC website